Lantheus to present data on PET imaging agents at SNM meeting

05/19/2010 | (free registration)

Lantheus Medical Imaging said it will present initial data from a Phase II trial of its myocardial perfusion PET imaging agent, flurpiridaz F-18, at the upcoming SNM meeting. The company also will present Phase I results on its LMI1195 cardiac neuronal PET imaging agent.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID